Table 2.
Treatment results
| Patient No. | Dose (Gy)/fraction | Alkaline phosphatase (35 - 104 IU/L)* | Total bilirubin (0.2 - 1.2 mg/dL)* | Aspartate transaminase (0 - 40 IU/L)* | Alanine transaminase (0 - 40 IU/L)* | Post-RT chemo-therapy | Survival from RT (day) |
|---|---|---|---|---|---|---|---|
| 1 | 21/7 | †N (306) | Y (6.5 → 2.2, 66%) | Y (118 → 69, 42%) | Y (43 → 27, 37%) | Y | 123 |
| 2 | 21/7 | ‡Y (1246 → 350, 72%) | Y (3.0 → 1.6, 47%) | Y (114 → 29, 75%) | Y (43 → 7, 84%) | Y | 94 |
| 3 | 21/7 | N (554) | N (1.8) | Y (152 → 109, 28%) | Y (30 → 18, 40%) | N | 64 |
| 4 | 21/7 | Y (432 → 297, 31%) | Y (1.7 → 1.2, 29%) | Y (60 → 24, 60%) | Y (35 → 13, 63%) | N | 22 |
| 5 | 21/7 | Y (415 → 89, 79%) | Y (3.2 → 1.0, 69%) | Y (197 → 20, 90%) | Y (80 → 13, 84%) | Y | 289 |
| 6 | 21/7 | Y (675 → 366, 46%) | Y (15.8 → 4.2, 73%) | Y (101 → 33, 67%) | Y (49 → 23, 53%) | N | 44 |
| 7 | 30/10 | Y (1093 → 613, 44%) | Y (36.7 → 9.2, 75%) | Y (250 → 124, 50%) | Y (123 → 31, 75%) | Y | 65 |
| 8 | 21/7 | Y (615 → 376, 39%) | N (1.3) | Y (88 → 69, 22%) | Y (25 → 15, 40%) | N | 34 |
| 9 | 21/7 | Y (404 → 348, 14%) | N (7.0) | N (42) | Y (31 → 19, 39%) | N | 44 |
| 10 | 21/7 | Y (612 → 500, 18%) | N (8.4) | Y (142 → 107, 25%) | Y (76 → 30, 61%) | N | 20 |
*Normal range
†No improvement in liver function test. Level before RT in parentheses
‡Improvement in liver function test. Levels before and after RT, and the reduction rate in parentheses